<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://oncologytube.com/videoEmbed/29029/magnify-study-phase-3-study-of-lenalidomide-revlimid-plus-rituximab-rituxan-followed-by-maintenance-therapy-in-relapsed-refractory-nhl-?channelName=AnnualCancerMeeting&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

MAGNIFY Study: Phase 3 Study Of Lenalidomide (Revlimid) P...

Name: MAGNIFY Study: Phase 3 Study Of Lenalidomide (Revlimid) P...
Uploaded: 2019-06-03T10:46:58
Duration: 3 min 40 s
Description: David Andorsky MD Of US Oncology Research Discusses MAGNIFY Study: Phase 3 Study Of Lenalidomide (Revlimid) Plus Rituximab (Rituxan) Followed By Maintenance Therapy In Relapsed/Refractory NHL.

$MAGNIFY Study: Phase 3 Study Of Lenalidomide (Revlimid) Plus Rituximab (Rituxan) Followed By Maintenance Therapy In Relapsed/Refractory NHL.$

00:03:40

Annual Meeting

3 years 74 Views

Share Add to Report 0 0

Embed (Iframe):

<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://oncologytube.com/videoEmbed/29029/magnify-study-phase-3-study-of-lenalidomide-revlimid-plus-rituximab-rituxan-followed-by-maintenance-therapy-in-relapsed-refractory-nhl-?channelName=AnnualCancerMeeting&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

Embed (Object):

<div class="embed-responsive embed-responsive-16by9"><object width="640" height="360"><param name="movie" value="https://oncologytube.com/videoEmbed/29029/magnify-study-phase-3-study-of-lenalidomide-revlimid-plus-rituximab-rituxan-followed-by-maintenance-therapy-in-relapsed-refractory-nhl-?channelName=AnnualCancerMeeting&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit="></param><param name="allowFullScreen" value="true"></param><param name="allowscriptaccess" value="always"></param><embed src="https://oncologytube.com/videoEmbed/29029/magnify-study-phase-3-study-of-lenalidomide-revlimid-plus-rituximab-rituxan-followed-by-maintenance-therapy-in-relapsed-refractory-nhl-?channelName=AnnualCancerMeeting&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" allowscriptaccess="always" allowfullscreen="true" width="640" height="360"></embed></object></div>

Link (HTML):

<a href="https://oncologytube.com/v/29029?channelName=AnnualCancerMeeting"><img src="https://oncologytubecom.cdn.ypt.me/videos/video_190603224658_49c3/video_190603224658_49c3.jpg?cache=15669162801678829655">MAGNIFY Study: Phase 3 Study Of Lenalidomide (Revlimid) Plus Rituximab (Rituxan) Followed By Maintenance Therapy In Relapsed/Refractory NHL.</a>

Link (BBCode):

[url=https://oncologytube.com/v/29029?channelName=AnnualCancerMeeting][img]https://oncologytubecom.cdn.ypt.me/videos/video_190603224658_49c3/video_190603224658_49c3.jpg?cache=15669162801678829655[/img]MAGNIFY Study: Phase 3 Study Of Lenalidomide (Revlimid) Plus Rituximab (Rituxan) Followed By Maintenance Therapy In Relapsed/Refractory NHL.[/url]

Sign in now!

Permanent Link

URL Friendly (SEO)

Current Time (SEO)

Category:

Lymphoma

Description:

David Andorsky MD Of US Oncology Research Discusses MAGNIFY Study: Phase 3 Study Of Lenalidomide (Revlimid) Plus Rituximab (Rituxan) Followed By Maintenance Therapy In Relapsed/Refractory NHL.